THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michelle Callegan to Keratitis

This is a "connection" page, showing publications Michelle Callegan has written about Keratitis.
Connection Strength

1.424
  1. Checks and balances: the ocular response to infection. Virulence. 2010 Jul-Aug; 1(4):222.
    View in: PubMed
    Score: 0.350
  2. Ocular Glands Become Infected Secondarily to Infectious Keratitis and Play a Role in Corneal Resistance to Infection. J Virol. 2019 08 15; 93(16).
    View in: PubMed
    Score: 0.164
  3. Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Curr Eye Res. 1994 Dec; 13(12):875-8.
    View in: PubMed
    Score: 0.119
  4. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet. 1994 Aug; 27(2):129-49.
    View in: PubMed
    Score: 0.116
  5. Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis. Infect Immun. 1994 Jun; 62(6):2478-82.
    View in: PubMed
    Score: 0.115
  6. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci. 1994 Mar; 35(3):1033-7.
    View in: PubMed
    Score: 0.113
  7. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992 Oct; 33(11):3017-23.
    View in: PubMed
    Score: 0.102
  8. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009 Apr; 26(4):447-54.
    View in: PubMed
    Score: 0.080
  9. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther. 2003 Sep-Oct; 20(5):246-52.
    View in: PubMed
    Score: 0.055
  10. Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci. 2002 May; 43(5):1414-21.
    View in: PubMed
    Score: 0.050
  11. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun. 1997 May; 65(5):1571-8.
    View in: PubMed
    Score: 0.035
  12. Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci. 1996 Mar; 37(4):534-43.
    View in: PubMed
    Score: 0.032
  13. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol. 1996; 40(2):212-9.
    View in: PubMed
    Score: 0.032
  14. Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea. Curr Eye Res. 1995 Apr; 14(4):281-4.
    View in: PubMed
    Score: 0.030
  15. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995 Mar; 14(3):229-34.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES